Menu Back toSession 3: Digital Technology Advances The Modernization Of Regulatory Science & Drug Development

DIA Asia 2021-The Evolution Of Clinical Trials And Regulatory Science In A Post-Pandemic Digital World In Asia

The timing is as per Singapore Time Zone

Session 3: Digital Technology Advances The Modernization Of Regulatory Science & Drug Development

Session Chair(s)

Vicky (Fengyun)  Han

Vicky (Fengyun) Han

  • Senior Director, Asia Pacific Regulatory Policy Group Lead, Asia Pacific
  • Johnson & Johnson Pte. Ltd., Singapore
Rie  Matsui, RPh

Rie Matsui, RPh

  • Senior Director, Regional Labeling Head for APAC
  • Japan
Digital is a very dynamic and developing in a very fast manner, it has been wildly applied in almost everywhere and has been accelerated during the COVID-19 pandemic. the pharmaceutical industry and academia have been using many digital tools to accelerate the drug R&D and clinical trial development, and regulator is leveraging the digital technology to improve its drug review and supervision system etc. In this session, will focus on updating of digital technology to advance the regulatory system modernization, and the transitioning to e-labelling by using 2D barcode and structured format, and digital endpoint to facilitating the clinical trial development and cloud based system


Tomoko  Ohsawa, PhD

Formal implementation of e-labelling in Japan

Tomoko Ohsawa, PhD

  • Director of Office of Informatics and Management for Safety
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Tong  Guo

De-centralised Clinical Trial in China: Progress and Practice

Tong Guo

  • Executive Vice President
  • LinkDoc Technology (Beijing) Co. Ltd, China
Kai  Langel

Digital Endpoint Ecosystem & Protocols

Kai Langel

  • Senior Director, Strategy and Innovation, Global Regulatory Policy
  • Janssen, Spain

Contact us

Registration Questions?

Send Email
+91 9029098844